High-risk neuroblastoma: targeted therapy could be used in first line treatment - Institut Curie
Because ALK can be targeted therapeutically, this study makes a compelling case for the introduction of ALK inhibitors in the initial treatment of high‑risk neuroblastoma patients with alterations in this gene.
An international study carried out by the SIOPEN consortium and published in the Journal of Clinical Oncology demonstrates that ALK gene alterations (mutation or amplification) are present in ~14 % and ~4 % of newly diagnosed high‑risk neuroblastoma patients, respectively, and that these alterations are associated with a lower overall survival. Because ALK can be targeted therapeutically, the authors argue that ALK inhibitors should be introduced at diagnosis for patients with ALK‑positive disease.
ALK‑positive high‑risk neuroblastoma has a poorer prognosis and represents a suitable target for the first‑line use of ALK inhibitors, potentially improving survival.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States
- Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study